Logo V rgb original.jpg
BlossomHill Therapeutics Closes $71M Series A Financing
March 03, 2021 16:01 ET | BlossomHill Therapeutics, Inc.
SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71...
Logo-InveniAI.png
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
June 02, 2020 08:00 ET | InveniAI
GUILDFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across...
Iterum Logo.jpg
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 12, 2020 06:45 ET | Iterum Therapeutics plc
 --Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria
February 21, 2020 08:00 ET | Arch Biopartners
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) --  Arch...
Sinuwave Technologies Receives 2019 President’s Choice Award at the 17th World Congress of the International Photodynamic Association
July 11, 2019 16:40 ET | International Photodynamic Association
Boston, USA, July 11, 2019 (GLOBE NEWSWIRE) -- At the 17th International Photodynamic Association World Congress in Boston, Massachusetts, Sinuwave Technologies Corporation, a subsidiary of Ondine...
Melinta Therapeutics
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 16:00 ET | Melinta Therapeutics
~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...
Melinta Therapeutics
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
May 07, 2019 07:30 ET | Melinta Therapeutics
MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
logo.png
Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance
March 27, 2018 09:08 ET | Arch Biopartners
TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S....
logo.png
Arch Biopartners Arranges Convertible Note Financing
February 08, 2018 07:30 ET | Arch Biopartners
TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
Melinta Therapeutics
Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
October 10, 2017 08:00 ET | Melinta Therapeutics
NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...